July 8, 2014
The Ministry of Health, Labor and Welfare (MHLW) on July 4 approved 32 pharmaceutical products, including Bristol-Myers K.K.’s interferon (IFN)-free hepatitis C treatments Daklinza Tablets 60 mg (daclatasvir) and Sunvepra Capsules 100 mg (asunaprevir).read more